Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2016 06:00 ET | Source: Foamix, Ltd.

Foamix Reports First Quarter 2016 Financial Results and Provides Business Update

REHOVOT, Israel, May 10, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing...
May 09, 2016 07:00 ET | Source: Foamix, Ltd.

Foamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101

REHOVOT, Israel, and BRIDGEWATER, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
May 03, 2016 08:00 ET | Source: Foamix, Ltd.

Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea

REHOVOT, Israel and BRIDGEWATER, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company...
April 28, 2016 08:00 ET | Source: Foamix, Ltd.

Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Tuesday, May 10

REHOVOT, Israel and BRIDGEWATER, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company...
March 09, 2016 00:00 ET | Source: Foamix, Ltd.

Foamix to Present Corporate Overview at the Barclays Global Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, N.J., March 09, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company...
March 07, 2016 08:00 ET | Source: Foamix, Ltd.

Foamix to Present Corporate Overview at the 28th Annual ROTH Conference

REHOVOT, Israel and BRIDGEWATER, N.J., March 07, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company...
March 03, 2016 07:00 ET | Source: Foamix, Ltd.

Foamix Reports Fiscal Year 2015 Financial Results and Provides Business Update

REHOVOT, Israel and BRIDGEWATER, N.J., March 03, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company...
February 29, 2016 08:00 ET | Source: Foamix, Ltd.

Foamix to Present Corporate Overview at the 36th Annual Cowen & Company Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company...
February 18, 2016 08:00 ET | Source: Foamix, Ltd.

Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2015 Financial Results Conference Call & Webcast Scheduled for Thursday, March 3

REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company...
January 07, 2016 16:01 ET | Source: Foamix, Ltd.

Foamix Announces Positive Results From Phase 1 Study to Characterize Minocycline Bioavailability of FMX-101 Compared to Solodyn® (Minocycline HCl) Extended-Release Tablets

Minocycline Systemic Bioavailability For FMX-101 Was More Than 100 Times Lower Than That For Solodyn. FMX-101 Was Well-Tolerated. REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 07, 2016 (GLOBE...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right